ポンペ病治療の世界市場予測(~2025年)

【英語タイトル】Global Pompe Disease Treatment Market Research Report Forecast to 2025

Market Research Futureが出版した調査資料(MRF9DC032)・商品コード:MRF9DC032
・発行会社(調査会社):Market Research Future
・発行日:2019年10月
・ページ数:78
・レポート言語:英語
・レポート形式:PDF
・納品方法:Eメール
・調査対象地域:グローバル
・産業分野:ヘルスケア
◆販売価格オプション(消費税別)
Single User(印刷不可、Online Access)USD4,450 ⇒換算¥489,500見積依頼/購入/質問フォーム
Enterprisewide Price(印刷可)USD6,250 ⇒換算¥687,500見積依頼/購入/質問フォーム
販売価格オプションの説明
※お支払金額:換算金額(日本円)+消費税
※納期:即日〜2営業日(3日以上かかる場合は別途表記又はご連絡)
※お支払方法:納品日+5日以内に請求書を発行・郵送(請求書発行日より2ヶ月以内に銀行振込、振込先:三菱UFJ銀行/H&Iグローバルリサーチ株式会社、支払期限と方法は調整可能)
当調査レポートでは、ポンペ病治療の世界市場について調査・分析し、エグゼクティブサマリー、市場紹介、調査方法、市場動向、市場要因分析、タイプ別(遅発性ポンペ病、典型的乳児発症ポンペ病、非典型的乳児発症ポンペ病)分析、用途別(近視、遠視)分析、治療別(酵素補充療法(ERT)、遺伝子治療)分析、エンドユーザー別(病院および診療所、研究および学術機関)分析、地域別分析、競合分析、会社概要などを含め、以下の構成でお届けします。
・エグゼクティブサマリー
・市場紹介
・調査方法
・市場動向
・市場要因分析
・ポンペ病治療の世界市場:タイプ別(遅発性ポンペ病、典型的乳児発症ポンペ病、非典型的乳児発症ポンペ病)
・ポンペ病治療の世界市場:用途別(近視、遠視)
・ポンペ病治療の世界市場:治療別(酵素補充療法(ERT)、遺伝子治療)
・ポンペ病治療の世界市場:エンドユーザー別(病院および診療所、研究および学術機関)
・ポンペ病治療の世界市場:地域別分析
・競合分析
・会社概要
【レポートの概要】

Pompe Disease Treatment Market Research Report – Global Forecast till 2025
Global Pompe Disease Treatment Market: Information by Type (Late-Onset Pompe Disease, Classic Infantile-Onset Pompe Disease, Non-Classic Infantile-Onset Pompe Disease), by Therapy (Enzyme Replacement Therapy (ERT) and Gene Therapy), End User (Hospitals & Clinics and Research & Academic Institutes) and Region (Americas, Europe, Asia-Pacific and the Middle East & Africa) – Forecast till 2025

Market Analysis
Pompe disease is a genetic metabolic disorder that is usually seen in infants. This disease is caused due to the mutations in the GAA gene which produces the acid, alpha-glucosidase enzyme, that translates glycogen into a simple form. The absence or mutation in the GAA gene results in the accumulation of glycogen that creates heart problems, muscle weakness, and liver harm that can lead to early death in newborns. Factors such as limited awareness about treatment methods and the high cost of therapy hinder market growth. The key factors that drive the Pompe disease treatment market are increasing government initiatives and increasing R&D by manufacturers. The Global Pompe Disease Treatment Market is likely to register a CAGR of 2.6% to attain USD 1,414.1 Million by the year 2025. The Orphan Products Grants funded 18 new grants from a total of 92 grant applications in 2015, to support around 67 ongoing clinical studies that are related to rare diseases as the government has been taking continuous initiatives for the progress and manufacture of advanced products for the diagnosis and treatment of rare diseases such as Pompe disease. Additionally, the governments of various countries such as Sweden, India, the Netherlands, and South Korea are focusing on approving guidelines for the reimbursement of patients enduring enzyme replacement therapy (ERT) for the treatment of Pompe disease. The State Government of Karnataka along with the Employee State Insurance Corporation provides free of cost ERT to patients with lysosomal storage disorders. Additionally, the Union Ministry of Health and Family Welfare has been taking active initiatives for producing a fund of an amount of 13,940 USD million for the treatment of rare diseases, including lysosomal storage disorders. These growing government initiatives for promoting and advancing Pompe disease treatment solutions are widely expected to spur growth of the global Pompe disease treatment market.

Market Segmentation
Global Pompe Disease Treatment Market has been segmented on the different basis. Based on Type the market has been segmented into Late-Onset Pompe Disease, Classic Infantile-Onset Pompe Disease and Non-Classic Infantile-Onset Pompe Disease. Based on Therapy, the Global Pompe Disease Treatment Market has been segmented into Enzyme Replacement Therapy (ERT) and Gene Therapy. Based on End User the market has been segmented into hospitals & Clinics and Research & Academic Institutes. Based on region the market has been segmented into different regions like Americas covering North America ( US and Canada) and South America, Europe covering Germany, UK, France, Spain, Italy and Rest of Europe, Asia-Pacific covering China, India, Japan, Australia & New Zealand, Southeast Asia and Rest of Asia-Pacific, Middle East & Africa. The acid alpha-glucosidase is responsible for breaking glycogen, a complex form of sugar, into its simple form. The absence or mutation in the GAA gene leads to the accumulation of glycogen and damages the cells and Pompe disease is a infrequent genetic condition, caused due to the mutation in the GAA gene, which is responsible for making an enzyme called acid alpha-glucosidase. tissues. There are three chief segmentation of Pompe disease, each differing based on age and severity. These different segments are late-onset Pompe disease, non-classic infantile-onset Pompe disease, and classic infantile-onset Pompe disease. The treatment of Pompe disease is disease-specific and depends on the symptoms of the disease. The global Pompe disease treatment market on the basis of therapy has been divided into, enzyme replacement therapy (ERT), gene therapy, and others. The enzyme replacement therapy (ERT) segment captures the maximum share of the total market as it is the only Food and Drug Administration (FDA) approved therapy for the treatment of Pompe diseases. The Pompe disease treatment market has been fragmented, on the basis of end user, into hospitals & clinics and research & academic institutes. The hospitals & clinics segment was valued at USD 860.8 million in the year 2018, and the research & academic institutes segment accounted for a value of USD 320.7 million in 2018 and are expected to exhibit a CAGR of 2.3% during the forecast period.

Regional Analysis
Geographically, the global Pompe disease treatment market, based on region, has been split into different regions like Americas, Europe, Asia-Pacific, and the Middle East & Africa.The Americas is responsible for the major share in the global Pompe disease treatment market owing to the grow in the number of patients with Pompe disease. As per the National Organization for Rare Disorders, the anticipated frequency of the occurrence Pompe disease is approximately 1 in 40,000 in the US. European Pompe disease treatment market is second largest market followed by Asia-Pacific. Europe responsible for the second-major market share in the Pompe disease treatment market owing to factors such as the growing research and development initiatives, support by government for the healthcare sector, and development in settlement policies have improved the market growth. Asia-Pacific is expected to be the fastest-growing region in the global Pompe disease treatment market during the forecast period. increasing healthcare expenditures, growing awareness among patients regarding rare disorders, and improved healthcare are factors which is affecting the the growth of the market. Due to low per capita income and absence of suitable healthcare infrastructure support, the Middle East & Africa responsible for a comparatively lesser market share in the year 2018

Major Players
The proposed spectators in global Pompe disease treatment market are hospitals, medical devices companies, Research and academic institutes, software companies Governments, associations, industrial bodies, etc. The major companies functioning in the global Pompe disease treatment market are concentrating on firming their global ways by entering into untouched markets. The projected onlookers of the global Pompe disease treatment market are Market research and consulting service providers, Medical research laboratories and Academic medical institutes and universities, Drug Suppliers, Research and development (R&D) companies, Government research laboratories, Independent research laboratories, Government and independent regulatory authorities. Oxyrane, Valerion Therapeutics, AVROBIO, Inc., and CENTOGENE AG., Amicus Therapeutics, Inc., Genzyme Corporation, Audentes Therapeutics are some of major players in the global Pompe disease treatment market. The players operating in the global Pompe disease treatment market is focusing on product launches, along with expanding their global footprints by entering untapped markets.

【レポートの目次】

Table of Contents:

1 Executive Summary
1.1 Introduction
2 Market Introduction
2.1 Scope of the Study
2.2 Research Objective
2.3 List of Assumptions
3 Research Methodology
3.1 Research Process
3.2 Primary Research
3.3 Secondary Research
3.4 Market Size Estimation
4 Market Dynamics
4.1 Introduction
4.2 Drivers
4.2.1 Increasing Government Initiatives
4.2.2 Rising R&D Activities by Manufacturers
4.3 Restraints
4.3.1 High Cost of Treatment
4.4 Opportunities
4.4.1 Emergence of Immunotherapeutic Approaches
4.5 Challenges
5 Market Factor Analysis
5.1 Value Chain Analysis
5.1.1 R&D and Designing
5.1.2 Manufacturing
5.1.3 Distribution & Sales
5.1.4 Post-Sales Services
5.2 Porter’s Five Forces Model
5.2.1 Bargaining Power of Suppliers
5.2.2 Bargaining Power of Buyers
5.2.3 Threat of New Entrants
5.2.4 Threat of Substitutes
5.2.5 Intensity of Rivalry
6 Global Pompe Disease Treatment Market, by Type
6.1 Introduction
6.2 Late-Onset Pompe Disease
6.3 Classic Infantile-Onset Pompe Disease
6.4 Non-Classic Infantile-Onset Pompe Disease
7 Global Pompe Disease Treatment Market, by Therapy
7.1 Introduction
7.2 Enzyme Replacement Therapy (ERT)
7.3 Gene Therapy
8 Global Pompe Disease Treatment Market, by End User
8.1 Introduction
8.2 Hospitals & Clinics
8.3 Research & Academic Institutes
9 Global Pompe Disease Treatment Market, by Region
9.1 Introduction
9.2 Americas
9.2.1 North America
9.2.1.1 US
9.2.1.2 Canada
9.2.2 South America
9.3 Europe
9.3.1 Germany
9.3.2 France
9.3.3 UK
9.3.4 Italy
9.3.5 Spain
9.3.6 Rest of Europe
9.4 Asia-Pacific
9.4.1 China
9.4.2 Japan
9.4.3 India
9.4.4 South Korea
9.4.5 Australia
9.4.6 Rest of Asia-Pacific
9.5 Middle East & Africa
9.5.1 Middle East
9.5.2 Africa
10 Competitive Landscape
10.1 Introduction
10.2 Key developments
11 Company Profiles
11.1 Amicus Therapeutics, Inc
11.1.1 Company Overview
11.1.2 Financial Overview
11.1.3 Products/Services Offered
11.1.4 Key Developments
11.1.5 SWOT Analysis
11.1.6 Key Strategies
11.2 Genzyme Corporation
11.2.1 Company Overview
11.2.2 Financial Overview
11.2.3 Products/Services Offered
11.2.4 Key Developments
11.2.5 SWOT Analysis
11.2.6 Key Strategies
11.3 Audentes Therapeutics
11.3.1 Company Overview
11.3.2 Financial Overview
11.3.3 Products/Services Offered
11.3.4 Key Developments
11.3.5 SWOT Analysis
11.3.6 Key Strategies
11.4 Oxyrane
11.4.1 Company Overview
11.4.2 Financial Overview
11.4.3 Products/Services Offered
11.4.4 Key Developments
11.4.5 SWOT Analysis
11.4.6 Key Strategies
11.5 Valerion Therapeutics
11.5.1 Company Overview
11.5.2 Financial Overview
11.5.3 Products/Services Offered (Clinical Study)
11.5.4 Key Developments
11.5.5 SWOT Analysis
11.5.6 Key Strategies
11.6 AVROBIO, Inc.
11.6.1 Company Overview
11.6.2 Financial Overview
11.6.3 Products/Services Offered
11.6.4 Key Developments
11.6.5 SWOT Analysis
11.6.6 Key Strategies
11.7 CENTOGENE AG
11.7.1 Company Overview
11.7.2 Financial Overview
11.7.3 Products/Services Offered
11.7.4 Key Developments
11.7.5 SWOT Analysis
11.7.6 Key Strategies
12 Appendix
12.1 References
12.2 Related Reports

List of Tables:

TABLE 1 LIST OF ASSUMPTIONS
TABLE 2 PRIMARY INTERVIEWS
TABLE 3 GLOBAL POMPE DISEASE TREATMENT MARKET, BY TYPE 2016–2025 (USD MILLION)
TABLE 4 GLOBAL POMPE DISEASE TREATMENT MARKET, FOR LATE-ONSET POMPE DISEASE, BY REGION 2016–2025 (USD MILLION)
TABLE 5 GLOBAL POMPE DISEASE TREATMENT MARKET, FOR CLASSIC INFANTILE-ONSET POMPE DISEASE, BY REGION 2016–2025 (USD MILLION)
TABLE 6 GLOBAL POMPE DISEASE TREATMENT MARKET, FOR NON-CLASSIC INFANTILE-ONSET POMPE DISEASE, BY REGION 2016–2025 (USD MILLION)
TABLE 7 GLOBAL POMPE DISEASE TREATMENT MARKET, BY THERAPY 2016–2025 (USD MILLION)
TABLE 8 GLOBAL POMPE DISEASE TREATMENT MARKET, FOR ENZYME REPLACEMENT THERAPY (ERT), BY REGION 2016–2025 (USD MILLION)
TABLE 9 GLOBAL POMPE DISEASE TREATMENT MARKET, FOR GENE THERAPY, BY REGION 2016–2025 (USD MILLION)
TABLE 10 GLOBAL POMPE DISEASE TREATMENT MARKET, BY END USER 2016–2025 (USD MILLION)
TABLE 11 GLOBAL POMPE DISEASE TREATMENT MARKET, FOR HOSPITALS & CLINICS, BY REGION 2016–2025 (USD MILLION)
TABLE 12 GLOBAL POMPE DISEASE TREATMENT MARKET, FOR RESEARCH & ACADEMIC INSTITUTES, BY REGION 2016–2025 (USD MILLION)
TABLE 13 GLOBAL POMPE DISEASE TREATMENT MARKET, BY REGION 2016–2025 (USD MILLION)
TABLE 14 AMERICAS: POMPE DISEASE TREATMENT MARKET, BY REGION 2016–2025 (USD MILLION)
TABLE 15 AMERICAS: POMPE DISEASE TREATMENT MARKET, BY TYPE 2016–2025 (USD MILLION)
TABLE 16 AMERICAS: POMPE DISEASE TREATMENT MARKET, BY THERAPY 2016–2025 (USD MILLION)
TABLE 17 AMERICAS: POMPE DISEASE TREATMENT MARKET, BY END USER 2016–2025 (USD MILLION)
TABLE 18 NORTH AMERICA: POMPE DISEASE TREATMENT MARKET, BY COUNTRY 2016–2025 (USD MILLION)
TABLE 19 NORTH AMERICA: POMPE DISEASE TREATMENT MARKET, BY TYPE 2016–2025 (USD MILLION)
TABLE 20 NORTH AMERICA: POMPE DISEASE TREATMENT MARKET, BY THERAPY 2016–2025 (USD MILLION)
TABLE 21 NORTH AMERICA: POMPE DISEASE TREATMENT MARKET, BY END USER 2016–2025 (USD MILLION)
TABLE 22 US: POMPE DISEASE TREATMENT MARKET, BY TYPE 2016–2025 (USD MILLION)
TABLE 23 US: POMPE DISEASE TREATMENT MARKET, BY THERAPY 2016–2025 (USD MILLION)
TABLE 24 US: POMPE DISEASE TREATMENT MARKET, BY END USER 2016–2025 (USD MILLION)
TABLE 25 CANADA: POMPE DISEASE TREATMENT MARKET, BY TYPE 2016–2025 (USD MILLION)
TABLE 26 CANADA: POMPE DISEASE TREATMENT MARKET, BY THERAPY 2016–2025 (USD MILLION)
TABLE 27 CANADA: POMPE DISEASE TREATMENT MARKET, BY END USER 2016–2025 (USD MILLION)
TABLE 28 SOUTH AMERICA: POMPE DISEASE TREATMENT MARKET, BY TYPE 2016–2025 (USD MILLION)
TABLE 29 SOUTH AMERICA: POMPE DISEASE TREATMENT MARKET, BY THERAPY 2016–2025 (USD MILLION)
TABLE 30 SOUTH AMERICA: POMPE DISEASE TREATMENT MARKET, BY END USER 2016–2025 (USD MILLION)
TABLE 31 EUROPE: POMPE DISEASE TREATMENT MARKET, BY COUNTRY/REGION 2016–2025 (USD MILLION)
TABLE 32 EUROPE: POMPE DISEASE TREATMENT MARKET, BY TYPE 2016–2025 (USD MILLION)
TABLE 33 EUROPE: POMPE DISEASE TREATMENT MARKET, BY THERAPY 2016–2025 (USD MILLION)
TABLE 34 EUROPE: POMPE DISEASE TREATMENT MARKET, BY END USER 2016–2025 (USD MILLION)
TABLE 35 GERMANY: POMPE DISEASE TREATMENT MARKET, BY TYPE 2016–2025 (USD MILLION)
TABLE 36 GERMANY: POMPE DISEASE TREATMENT MARKET, BY THERAPY 2016–2025 (USD MILLION)
TABLE 37 GERMANY: POMPE DISEASE TREATMENT MARKET, BY END USER 2016–2025 (USD MILLION)
TABLE 38 FRANCE: POMPE DISEASE TREATMENT MARKET, BY TYPE 2016–2025 (USD MILLION)
TABLE 39 FRANCE: POMPE DISEASE TREATMENT MARKET, BY THERAPY 2016–2025 (USD MILLION)
TABLE 40 FRANCE: POMPE DISEASE TREATMENT MARKET, BY END USER 2016–2025 (USD MILLION)
TABLE 41 UK: POMPE DISEASE TREATMENT MARKET, BY TYPE 2016–2025 (USD MILLION)
TABLE 42 UK: POMPE DISEASE TREATMENT MARKET, BY THERAPY 2016–2025 (USD MILLION)
TABLE 43 UK: POMPE DISEASE TREATMENT MARKET, BY END USER 2016–2025 (USD MILLION)
TABLE 44 ITALY: POMPE DISEASE TREATMENT MARKET, BY TYPE 2016–2025 (USD MILLION)
TABLE 45 ITALY: POMPE DISEASE TREATMENT MARKET, BY THERAPY 2016–2025 (USD MILLION)
TABLE 46 ITALY: POMPE DISEASE TREATMENT MARKET, BY END USER 2016–2025 (USD MILLION)
TABLE 47 SPAIN: POMPE DISEASE TREATMENT MARKET, BY TYPE 2016–2025 (USD MILLION)
TABLE 48 SPAIN: POMPE DISEASE TREATMENT MARKET, BY THERAPY 2016–2025 (USD MILLION)
TABLE 49 SPAIN: POMPE DISEASE TREATMENT MARKET, BY END USER 2016–2025 (USD MILLION)
TABLE 50 REST OF EUROPE: POMPE DISEASE TREATMENT MARKET, BY TYPE 2016–2025 (USD MILLION)
TABLE 51 REST OF EUROPE: POMPE DISEASE TREATMENT MARKET, BY THERAPY 2016–2025 (USD MILLION)
TABLE 52 REST OF EUROPE: POMPE DISEASE TREATMENT MARKET, BY END USER 2016–2025 (USD MILLION)
TABLE 53 ASIA-PACIFIC: POMPE DISEASE TREATMENT MARKET, BY COUNTRY/REGION 2016–2025 (USD MILLION)
TABLE 54 ASIA-PACIFIC: POMPE DISEASE TREATMENT MARKET, BY TYPE 2016–2025 (USD MILLION)
TABLE 55 ASIA-PACIFIC: POMPE DISEASE TREATMENT MARKET, BY THERAPY 2016–2025 (USD MILLION)
TABLE 56 ASIA-PACIFIC: POMPE DISEASE TREATMENT MARKET, BY END USER 2016–2025 (USD MILLION)
TABLE 57 CHINA: POMPE DISEASE TREATMENT MARKET, BY TYPE 2016–2025 (USD MILLION)
TABLE 58 CHINA: POMPE DISEASE TREATMENT MARKET, BY THERAPY 2016–2025 (USD MILLION)
TABLE 59 CHINA: POMPE DISEASE TREATMENT MARKET, BY END USER 2016–2025 (USD MILLION)
TABLE 60 JAPAN: POMPE DISEASE TREATMENT MARKET, BY TYPE 2016–2025 (USD MILLION)
TABLE 61 JAPAN: POMPE DISEASE TREATMENT MARKET, BY THERAPY 2016–2025 (USD MILLION)
TABLE 62 JAPAN: POMPE DISEASE TREATMENT MARKET, BY END USER 2016–2025 (USD MILLION)
TABLE 63 INDIA: POMPE DISEASE TREATMENT MARKET, BY TYPE 2016–2025 (USD MILLION)
TABLE 64 INDIA: POMPE DISEASE TREATMENT MARKET, BY THERAPY 2016–2025 (USD MILLION)
TABLE 65 INDIA: POMPE DISEASE TREATMENT MARKET, BY END USER 2016–2025 (USD MILLION)
TABLE 66 SOUTH KOREA: POMPE DISEASE TREATMENT MARKET, BY TYPE 2016–2025 (USD MILLION)
TABLE 67 SOUTH KOREA: POMPE DISEASE TREATMENT MARKET, BY THERAPY 2016–2025 (USD MILLION)
TABLE 68 SOUTH KOREA: POMPE DISEASE TREATMENT MARKET, BY END USER 2016–2025 (USD MILLION)
TABLE 69 AUSTRALIA: POMPE DISEASE TREATMENT MARKET, BY TYPE 2016–2025 (USD MILLION)
TABLE 70 AUSTRALIA: POMPE DISEASE TREATMENT MARKET, BY THERAPY 2016–2025 (USD MILLION)
TABLE 71 AUSTRALIA: POMPE DISEASE TREATMENT MARKET, BY END USER 2016–2025 (USD MILLION)
TABLE 72 REST OF ASIA-PACIFIC: POMPE DISEASE TREATMENT MARKET, BY TYPE 2016–2025 (USD MILLION)
TABLE 73 REST OF ASIA-PACIFIC: POMPE DISEASE TREATMENT MARKET, BY THERAPY 2016–2025 (USD MILLION)
TABLE 74 REST OF ASIA-PACIFIC: POMPE DISEASE TREATMENT MARKET, BY END USER 2016–2025 (USD MILLION)
TABLE 75 MIDDLE EAST & AFRICA: POMPE DISEASE TREATMENT MARKET, BY REGION 2016–2025 (USD MILLION)
TABLE 76 MIDDLE EAST & AFRICA: POMPE DISEASE TREATMENT MARKET, BY TYPE 2016–2025 (USD MILLION)
TABLE 77 MIDDLE EAST & AFRICA: POMPE DISEASE TREATMENT MARKET, BY THERAPY 2016–2025 (USD MILLION)
TABLE 78 MIDDLE EAST & AFRICA: POMPE DISEASE TREATMENT MARKET, BY END USER 2016–2025 (USD MILLION)
TABLE 79 MIDDLE EAST: POMPE DISEASE TREATMENT MARKET, BY TYPE 2016–2025 (USD MILLION)
TABLE 80 MIDDLE EAST: POMPE DISEASE TREATMENT MARKET, BY THERAPY 2016–2025 (USD MILLION)
TABLE 81 MIDDLE EAST: POMPE DISEASE TREATMENT MARKET, BY END USER 2016–2025 (USD MILLION)
TABLE 82 AFRICA: POMPE DISEASE TREATMENT MARKET, BY TYPE 2016–2025 (USD MILLION)
TABLE 83 AFRICA: POMPE DISEASE TREATMENT MARKET, BY THERAPY 2016–2025 (USD MILLION)
TABLE 84 AFRICA: POMPE DISEASE TREATMENT MARKET, BY END USER 2016–2025 (USD MILLION)
TABLE 85 MAJOR PLAYERS IN THE GLOBAL POMPE DISEASE TREATMENT MARKET
TABLE 86 KEY DEVELOPMENTS, BY PLAYERS IN THE MARKET

List of Figures:

FIGURE 1 MARKET SYNOPSIS
FIGURE 2 GLOBAL POMPE DISEASE TREATMENT MARKET: STRUCTURE
FIGURE 3 RESEARCH PROCESS
FIGURE 4 TOP-DOWN AND BOTTOM-UP APPROACHES
FIGURE 5 MARKET DYNAMICS: ANALYSIS OF THE GLOBAL POMPE DISEASE TREATMENT MARKET
FIGURE 6 VALUE CHAIN: GLOBAL POMPE DISEASE TREATMENT MARKET
FIGURE 7 PORTER’S FIVE FORCES ANALYSIS: GLOBAL POMPE DISEASE TREATMENT MARKET
FIGURE 8 GLOBAL POMPE DISEASE TREATMENT MARKET, BY TYPE 2018 & 2025 (USD MILLION)
FIGURE 9 GLOBAL POMPE DISEASE TREATMENT MARKET, BY THERAPY 2018 & 2025 (USD MILLION)
FIGURE 10 GLOBAL POMPE DISEASE TREATMENT MARKET, BY END USER 2018 & 2025 (USD MILLION)
FIGURE 11 GLOBAL POMPE DISEASE TREATMENT MARKET SHARE, BY REGION 2018 (%)
FIGURE 12 AMERICAS: POMPE DISEASE TREATMENT MARKET SHARE, BY REGION 2018 (%)
FIGURE 13 NORTH AMERICA: POMPE DISEASE TREATMENT MARKET SHARE, BY COUNTRY 2018 (%)
FIGURE 14 EUROPE: POMPE DISEASE TREATMENT MARKET SHARE, BY COUNTRY/REGION 2018 (%)
FIGURE 15 ASIA-PACIFIC: POMPE DISEASE TREATMENT MARKET SHARE, BYCOUNTRY/ REGION 2018 (%)
FIGURE 16 MIDDLE EAST & AFRICA: POMPE DISEASE TREATMENT MARKET SHARE, BY REGION 2018 (%)

【掲載企業】

Oxyrane, Valerion Therapeutics, AVROBIO, Inc., and CENTOGENE AG., Amicus Therapeutics, Inc., Genzyme Corporation, Audentes Therapeutics

★調査レポート[ポンペ病治療の世界市場予測(~2025年)] (コード:MRF9DC032)販売に関する免責事項を必ずご確認ください。
★調査レポート[ポンペ病治療の世界市場予測(~2025年)]についてメールでお問い合わせ


◆H&Iグローバルリサーチのお客様(例)◆